Literature DB >> 28561886

Improving symptom management for people with amyotrophic lateral sclerosis.

Katharine Nicholson1, Alyssa Murphy1, Erin McDonnell2, Jordan Shapiro3, Ericka Simpson4, Jonathan Glass5, Hiroshi Mitsumoto6, Dallas Forshew7, Robert Miller7, Nazem Atassi1.   

Abstract

INTRODUCTION: Symptomatic management is the main focus of ALS clinical care. We aim to report the prevalence of ALS-related symptoms and characterize self-reported symptomatic management.
METHODS: A symptom management survey developed by the Muscular Dystrophy Association Clinical Research Network was completed by ALS registrants. Logistic regression identified potential predictors of symptom prevalence, severity, and treatment.
RESULTS: A total of 567 ALS participants reported fatigue (90%), muscle stiffness (84%), and muscle cramps (74%) as most prevalent symptoms. Fatigue (18%), muscle stiffness (14%), and shortness of breath (12%) were most bothersome. Although fatigue was the most prevalent symptom, it was also least treated (10%). Neither location of care nor disease duration was associated with symptom prevalence, severity, or probability of receiving treatment. DISCUSSION: This large patient-reported symptom survey suggests that fatigue is the most prevalent, bothersome, and undertreated ALS symptom. Improving ALS symptom management is an unmet medical need and clinical trials of symptomatic treatments are needed. Muscle Nerve 57: 20-24, 2018.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  ALS; fatigue; self-reported; survey; symptom; symptomatic management

Mesh:

Year:  2017        PMID: 28561886     DOI: 10.1002/mus.25712

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  6 in total

1.  Symptom management in amyotrophic lateral sclerosis: We can do better.

Authors:  Stephen A Goutman; Zachary Simmons
Journal:  Muscle Nerve       Date:  2017-08-30       Impact factor: 3.217

Review 2.  SOD1 oligomers in amyotrophic lateral sclerosis.

Authors:  Esther S Choi; Nikolay V Dokholyan
Journal:  Curr Opin Struct Biol       Date:  2021-01-16       Impact factor: 6.809

Review 3.  Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis.

Authors:  Stephen A Goutman; Orla Hardiman; Ammar Al-Chalabi; Adriano Chió; Masha G Savelieff; Matthew C Kiernan; Eva L Feldman
Journal:  Lancet Neurol       Date:  2022-03-22       Impact factor: 59.935

4.  Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch.

Authors:  Angela Genge; Benjamin Rix Brooks; Björn Oskarsson; Alexander Kalin; Ming Ji; Stephen Apple; Laura Bower
Journal:  Drugs R D       Date:  2022-06-20

5.  Disability and Contextual Factors in Patients with Amyotrophic Lateral Sclerosis - A Three-Year Observational Study.

Authors:  Petter Sandstedt; Susanne Littorin; Sverker Johansson; Kristina Gottberg; Charlotte Ytterberg; Marie Kierkegaard
Journal:  J Neuromuscul Dis       Date:  2018

Review 6.  Qualitative measures that assess functional disability and quality of life in ALS.

Authors:  Susan L Hartmaier; Thomas Rhodes; Suzanne F Cook; Courtney Schlusser; Chao Chen; Steve Han; Neta Zach; Venkatesha Murthy; Shreya Davé
Journal:  Health Qual Life Outcomes       Date:  2022-01-21       Impact factor: 3.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.